GMDx Co Pty Ltd is a Gene Mutation Diagnostic company in a rapidly growing global market that is primed to adopt our significant R&D breakthroughs in genomic diagnostics.

GMDx Co has developed the world’s only comprehensive Innate Immune Fitness profiling (IIF) platform with applications including oncology, virology and other diseases.

Our patented Targeted Somatic Mutation (TSM) diagnostic test capabilities represent a novel set of advances in the area of genomic diagnostics that are based upon new disruptive genomic test algorithms that provide ‘actionable’ metrics for clinicians.

Our transformational platform technology is protected by granted patents and additional patent applications in jurisdictions including the US, Europe, Japan, China, Hong Kong and Australia.